Progress,implications,and challenges in using humanized immune system mice in CAR-T therapy-Application evaluation and improvement

作     者：Hanwei Yue Lin Bai Hanwei Yue;Lin Bai

作者机构：NHC Key Laboratory of Human Disease Comparative MedicineInstitute of Laboratory Animal SciencesCAMS and PUMCChao-yang DistrictBeijingChina 

出 版 物：《Animal Models and Experimental Medicine》 (动物模型与实验医学（英文）)

年 卷 期：2024年第7卷第1期

页      面：3-11页

核心收录：

学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 07[理学] 071002[理学-动物学] 

基　　金：CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2021-I2M-1-035 National Key Research and Development Project,Grant/Award Number:2022YFA1103803 

主　　题：antitumor antiviral CAR-T humanized immune system model humanized mice preclinical research 

摘      要：In recent years,humanized immune system(HIS)mice have been gradually used as models for preclinical research in pharmacotherapies and cell therapies with major breakthroughs in tumor and other fields,better mimicking the human immune system and the tumor immune microenvironment,compared to traditional immunodeficient *** better promote the application of HIS mice in preclinical research,we se-lectively summarize the current prevalent and breakthrough research and evaluation of chimeric antigen receptor(CAR)-T cells in various antiviral and antitumor *** exploring its application in preclinical research,we find that it can better reflect the actual clinical patient condition,with the advantages of providing high-efficiency detection indicators,even for progressive research and *** believe that it has better clinical patient simulation and promotion for the updated design of CAR-T cell therapy than directly transplanted immunodeficient *** characteristics of the main models are proposed to improve the use defects of the existing models by reducing the limitation of antihost reaction,combining multiple models,and unifying sources and organoid *** study of relapse and toxicity after CAR-T treatment also provides more possibilities for application and development.